dengue virus serotype 2 expressing dengue virus serotype 1 surface proteins, live attenuated

This drug is a live-attenuated chimeric dengue vaccine candidate designed to provide immunity against dengue virus serotype 1 (DENV-1). It consists of a dengue virus serotype 2 (DENV-2) genetic backbone, specifically the PDK-53 attenuated strain, in which the pre-membrane (prM) and envelope (E) genes have been replaced with the corresponding genes from a DENV-1 strain. This chimeric construction allows the vaccine to present DENV-1 surface antigens to the host immune system while maintaining the attenuation and safety characteristics of the DENV-2 PDK-53 backbone. Originally developed by Inviragen and subsequently acquired by Takeda, this construct (designated as TDV-1) is a primary component of the tetravalent dengue vaccine TAK-003 (Qdenga). Clinical development of this specific component involved significant collaboration with Umeå University and Region Västerbotten, particularly during early-phase clinical trials conducted in Sweden.

Other names

dengue virus serotype 2 expressing dengue virus serotype 1 surface proteins, live attenuatedchimeric DENV-2/1 vaccineDENV-1-PDK-53 live attenuated vaccineDENV1-PDK-53 live attenuated vaccineDENV 1-PDK-53 live attenuated vaccine